Increased cytoplasmic S100A6 expression is associated with pulmonary adenocarcinoma progression
Increased cytoplasmic S100A6 expression is associated with pulmonary adenocarcinoma progression
复制标题
DOI：
10.1111/j.1440-1827.2009.02417.x
复制
发表时间：
2009-09-01
影响因子：
2.2
通讯作者：
Noguchi, Masayuki
中科院分区：
文献类型：
--
作者：
Ishii, Aya;Suzuki, Meguri;Noguchi, Masayuki
S100 A6是一种钙结合蛋白，参与许多细胞过程，并在癌症中经常上调。最近有报道称，S100 A6基因在腺癌混合亚型中的表达高于纯BAC。为探讨S100 A6蛋白表达与肺腺癌分级进展的关系，应用免疫组化方法检测了92例肺腺癌组织中S100 A6蛋白的表达。对肿瘤细胞的细胞核和细胞质进行染色，并单独评估S100 A6的细胞核和细胞质表达。此外，选择6例冷冻手术标本，并在Western印迹上证实S100 A6的表达。因此，虽然不能检测到细胞核S100 A6免疫反应性与肿瘤进展之间的任何显著相关性，但晚期腺癌的胞浆S100 A6表达显著高于非侵袭性病变或正常肺组织（P < 0.05）。此外，BAC组分倾向于具有比任何其他组分更弱的染色。提示S100 A6基因可能与肺腺癌，尤其是BAC型肺腺癌的浸润和/或进展有关。本研究结果表明，实用程序的S100 A6免疫组化作为一个标志物，估计恶性腺癌与BAC组件。
S100A6 is a calcium-binding protein implicated in many cellular processes and frequently upregulated in cancer. Recently it was reported that S100A6 is one of the genes having higher expression in adenocarcinoma mixed subtype with a bronchioloalveolar carcinoma (BAC) component than in pure BAC. To clarify the association of S100A6 expression with stepwise progression of lung adenocarcinoma, S100A6 protein expression was examined on immunohistochemistry in 92 formalin-fixed and paraffin-embedded lung adenocarcinomas. Both the nucleus and cytoplasm of the tumor cells were stained, and the nuclear and cytoplasmic expression of S100A6 was assessed individually. In addition, six frozen surgical specimens were selected, and the expression of S100A6 was confirmed on western blotting. As a result, although it was not possible to detect any significant correlation between nuclear S100A6 immunoreactivity and tumor progression, advanced adenocarcinoma had significantly higher cytoplasmic S100A6 expression than non-invasive lesions or normal lung tissue (P < 0.05). Moreover, the BAC component tended to have weaker staining than any of the other components. These findings indicate that S100A6 may be associated with the stepwise progression and/or invasion of lung adenocarcinoma, especially BAC-type adenocarcinoma. The present results suggest the utility of S100A6 immunohistochemistry as a marker for estimation of malignancy in adenocarcinoma with a BAC component.